Tag: clinical trial sponsor FDA inspections

Lessons from FDA 483 Audit Findings in Clinical Trials What Lessons FDA 483 Audit Findings Teach Clinical Trial Sponsors Introduction: Understanding FDA 483 in Clinical Trials The FDA Form 483, “Inspectional Observations,” is issued when investigators identify deficiencies during inspections of clinical trial sites, sponsors, or CROs. In the context of clinical trials, FDA 483…

Read More “Lessons from FDA 483 Audit Findings in Clinical Trials” »